drugset / Trial / NCT02399189

MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma

NCT02399189

Phase 2 Unknown 39 enrolled Jun Zhu
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of chemotherapy with MT-R followed by autologous stem cells transplantation in newly-diagnosed primary central nervous system lymphoma.

Timeline

Start
2014-05
Primary completion
2017-04
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 3.5 g
Subject Rituximab Monoclonal antibody 375 mg/m2
Subject Temozolomide Small molecule 100 mg/m2
Subject Thiotepa Other / unclassified 5 mg/kg
Subject carmustine Small molecule 400 mg/m2